Table 1. Immune response to 23vPPV among Indigenous Australians receiving a first or second dose compared to first-dose non-Indigenous Australians.
|
Indigenous first dose (N=20) |
Indigenous second dose (N=20) |
Non-Indigenous first dose (N=20) |
||||
|---|---|---|---|---|---|---|
| Outcome | Pre | Post | Pre | Post | Pre | Post |
| Serotype-specific IgG (μg ml−1)a | ||||||
| 1 | 0.54 (0.37–0.77) | 2.45 (1.29–4.63) | 1.43** (0.93–2.20) | 3.41 (2.03–5.71) | 0.38 (0.25–0.56) | 9.78** (5.49–17.42) |
| 6B | 0.70 (0.45–1.09) | 2.85 (1.59–5.13) | 1.76** (1.04–2.97) | 4.44 (2.53–7.79) | 0.44 (0.30–0.64) | 2.87 (1.67–4.96) |
| 14 | 2.43 (1.35–4.37) | 12.3 (6.51–23.26) | 8.71** (4.83–15.69) | 17.98 (10.74–30.09) | 0.87* (0.46–17.46) | 6.51 (2.91–14.59) |
| 18C | 0.80 (0.44–1.46) | 3.72 (2.04–6.80) | 1.35 (0.84–2.18) | 4.05 (2.55–6.44) | 0.58 (0.35–0.98) | 7.77* (4.94–12.22) |
| 19A | 8.11 (5.2–12.64) | 10.65 (6.51–17.44) | 6.73 (4.46–27.65) | 10.16 (7.01–14.71) | 2.61*** (1.80–3.78) | 6.83 (4.28–10.90) |
| Opsonophagocytosis (OI)b | ||||||
| 1 | 5 (3–6) | 15 (6–39) | 5 (4–7) | 14 (6–32) | 4 (4–4) | 240 (88–655)*** |
| 6B | 16 (8–33) | 181 (70–468) | 16 (8–33) | 202 (70–583) | 6 (4–9)* | 131 (39–436) |
| 14 | 13 (5–33) | 244 (79–751) | 86 (30–251)** | 218 (78–610) | 9 (5–17) | 205 (72–581) |
| 18C | 16 (8–35) | 83 (30–231) | 14 (7–28) | 112 (43–290) | 6 (4–9)* | 191 (67–545) |
| 19A | 14 (7–29) | 62 (24–160) | 22 (9–51) | 95 (37–240) | 9 (5–18) | 108 (41–288) |
| Memory B cell ( × 106 PBMC per ml)c | ||||||
| 1 | 4.1 (1.7) | 3.8 (1.3) | 3.0 (1.0) | 2.6 (0.8) | 1.4 (0.9) | 4.6 (2.0) |
| 6B | 2.7 (0.9) | 1.7 (0.5) | 2.1 (0.6) | 1.2 (0.4) | 1.8 (0.6) | 4.6 (0.9)** |
| 14 | 1.9 (0.9) | 2.3 (1.0) | 2.3 (0.7) | 1.3 (0.5) | 1.0 (0.3) | 3.2 (1.1) |
| 18C | 4.3 (1.6) | 4.1 (1.7) | 3.8 (1.8) | 2.1 (0.6) | 1.6 (0.5) | 2.8 (0.7) |
| 19A | 3.5 (1.5) | 1.7 (0.6) | 4.0 (1.2) | 1.7 (0.4) | 1.7 (0.5) | 2.9 (0.7) |
Abbreviations: OI, opsonophagocytic index; PBMC, peripheral blood mononuclear cell; 23vPPV, 23-valent pneumococcal polysaccharide vaccine.
*P<0.05, **P<0.01, ***P<0.001 compared to Indigenous first-dose group.
a
Results expressed as geometric mean concentration (±95% confidence intervals).
b
Results expressed as geometric mean opsonophagocytic index (±95% confidence intervals).
c
Results expressed as mean (±s.e.m.). Serotype-specific IgG responses to the remaining serotypes in 23vPPV have been previously reported.4